Cite
HARVARD Citation
Xu, L. et al. (n.d.). 165P Efficacy and safety of tislelizumab (TIS) plus lenvatinib (LEN) as first-line treatment in patients (pts) with unresectable hepatocellular carcinoma (uHCC): A single-arm, multicenter, phase II trial. Immuno-oncology technology. p. . [Online].